EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings or view top-rated stocks.

3 analysts have issued 1-year price targets for EyePoint Pharmaceuticals' shares. Their EYPT share price forecasts range from $21.00 to $52.00. On average, they predict the company's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 1,011.1% from the stock's current price.
View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts.

EyePoint Pharmaceuticals' stock was trading at $3.50 at the start of the year. Since then, EYPT shares have decreased by 16.0% and is now trading at $2.94.
View the best growth stocks for 2023 here.

EyePoint Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,790,000 shares, an increase of 34.8% from the February 28th total of 2,070,000 shares. Based on an average trading volume of 280,300 shares, the short-interest ratio is presently 10.0 days. Currently, 10.9% of the shares of the company are short sold.
View EyePoint Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EYPT earnings forecast.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its earnings results on Wednesday, November, 3rd. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.11. The firm had revenue of $9.06 million for the quarter, compared to analyst estimates of $9.60 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 58.08% and a negative net margin of 246.97%. During the same quarter last year, the company earned ($0.30) EPS.

Shares of EyePoint Pharmaceuticals reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYPT stock can currently be purchased for approximately $2.94.

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $100.84 million and generates $41.40 million in revenue each year. The company earns $-102,250,000.00 in net income (profit) each year or ($2.73) on an earnings per share basis.

The company employs 122 workers across the globe.

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.